Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Valeant Pharmaceuticals to Acquire PharmaSwiss S.A.

By Pharmaceutical Processing | February 1, 2011

Valeant Pharmaceuticals International, Inc. and PharmaSwiss
S.A. have signed a binding agreement for Valeant to acquire PharmaSwiss, a
privately-owned branded generics and over-the-counter (OTC) pharmaceutical
company based in Zug, Switzerland for euro 350 million. Upon closing,
PharmaSwiss is expected to have approximately euro 38 million cash on hand and
no debt. Up to an additional euro 30 million may be payable to certain
stockholders of PharmaSwiss based upon achievement of certain milestones.

PharmaSwiss has a broad product portfolio in seven
therapeutic areas and operations in nineteen countries throughout Central and Eastern
Europe, including Poland, Hungary, the Czech
Republic and Serbia. The
company also has operations in Greece
and Israel.
In addition, PharmaSwiss is an existing partner to several large pharmaceutical
and biotech companies offering regional expertise in such functions as
regulatory, compliance, sales, marketing and distribution.  PharmaSwiss
had annual revenues of approximately euro 180 million in 2010 and has been
growing at approximately 20% per year over the past 5 years.  

The senior management team of PharmaSwiss will remain with
Valeant, including both the founder-partners, as well as Pavel Mirovsky, chief
executive officer of PharmaSwiss. All of them are expected to continue in their
leadership roles, working closely with the Valeant Europe team.  Mr.
Mirovsky will report directly to Valeant’s chief executive officer, J. Michael
Pearson.  Over time, it is anticipated the Valeant business in Central
Europe will be combined under the PharmaSwiss corporate structure, based in Zug, Switzerland.

The transaction, which is subject to customary closing
conditions, including certain regulatory approvals, is expected to close in the
first or second quarter of 2011 and to be immediately accretive to Valeant. After
synergies, it is expected that the operating income as a percentage of revenue
of the combined Central and Eastern European business will be similar to that
of Valeant’s historical branded generic European business.

“This acquisition of PharmaSwiss solidifies our
position as a leading pharmaceutical company in Central and Eastern
Europe,” said Mr. Pearson.  “PharmaSwiss has an
attractive partnering strategy as well as a complementary branded generics and
OTC product portfolio that will strengthen our presence in the region.”

“I am delighted that PharmaSwiss will be joining
Valeant,” commented Dr. Pavel Mirovsky. “Valeant’s additional
resources, professional approach, focused pipeline and strong commitment to
supporting all three legs of the PharmaSwiss business model (Representation of
multinationals, Licensing from specialty pharma, and Own Brands), will enable us
to build up our winning strategy of serving partners. Valeant Europe’s strong
presence in Poland,
the region’s largest market, fills an important gap and should contribute to
transaction synergies.  The message we want to send to our employees,
business partners and other stakeholders is one of continuity and commitment to
growth.”  

 

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards